Exscientia plc (NASDAQ:EXAI – Get Free Report) traded up 3.8% during mid-day trading on Wednesday . The stock traded as high as $5.27 and last traded at $5.22. 114,970 shares were traded during mid-day trading, a decline of 82% from the average session volume of 631,295 shares. The stock had previously closed at $5.03.
Analyst Ratings Changes
A number of equities analysts have commented on EXAI shares. Barclays reiterated an “equal weight” rating and issued a $5.00 price objective on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen reiterated a “hold” rating on shares of Exscientia in a research report on Friday, August 9th.
View Our Latest Report on Exscientia
Exscientia Trading Up 3.2 %
Exscientia (NASDAQ:EXAI – Get Free Report) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The firm had revenue of $5.60 million during the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. Equities analysts anticipate that Exscientia plc will post -1.25 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Novo Holdings A S bought a new position in shares of Exscientia in the second quarter valued at $66,742,000. Bank of New York Mellon Corp lifted its holdings in shares of Exscientia by 108.8% during the second quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock valued at $1,981,000 after purchasing an additional 202,377 shares during the last quarter. Jump Financial LLC boosted its position in shares of Exscientia by 47.7% in the 4th quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock valued at $345,000 after purchasing an additional 17,355 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in Exscientia during the 2nd quarter worth about $256,000. Finally, EntryPoint Capital LLC boosted its holdings in shares of Exscientia by 22.8% in the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after buying an additional 5,784 shares during the period. 41.58% of the stock is currently owned by institutional investors.
Exscientia Company Profile
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Read More
- Five stocks we like better than Exscientia
- Investing In Preferred Stock vs. Common Stock
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- Technology Stocks Explained: Here’s What to Know About Tech
- Stocks to Take Advantage of Rising Gold Prices
- Stock Dividend Cuts Happen Are You Ready?
- Smartsheet Is a Smart Buy for Traders and Investors: Here’s Why
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.